Journal Home
Search for

Volume 64, Issue 1, Pages 174-176 (2005)


View previous. 6 of 49 View next.

Immunosuppressive therapy for kidney transplant prevents vaso-occlusive crisis in a haemoglobin SC disease patient

J.A.B. ChiesaCorresponding Author Informationemail address, C. Drescha, M.S. Cruza, G. da Silvaa, E. Barrosb, C. Bittarc, J. Friedrischc, L.M.R. Sillac

Received 27 April 2004; accepted 3 May 2004. published online 19 August 2004.

Abstract 

Although the molecular basis of sickle cell disease (SCD) is well established, the wide variability in clinical manifestations still puzzles haematologists and clinicians. Recently, SCD started to be considered by different groups as a chronic inflammatory condition, where the inflammatory tendency of each individual could drive more or less severe clinical features. Here we describe a haemoglobin SC disease patient (heterozygous to both HbS and HbC variants) that experienced several vaso-occlusive crises before underwent a successful kidney transplantation. Since then (16 years ago), she is on uninterruped immunosuppressive therapy, and do not experienced any severe vaso-occlusive crisis. Considering SCD associated morbidity as a result of exacerbated immune responses, we suggest that the immunosuppressive therapy directed to the kidney graft maintenance is actually also helping in the control of the chronic inflammatory responses associated to SCD.

a Immunogenetics Laboratory, Department of Genetics, Universidade Federal do Rio Grande do Sul – UFRGS, Av Bento Gonçalves 9500, Predio 43 323, Caixa Postal 15053, CEP 91501-970, Porto Alegre, RS, Brazil

b Department of Internal Medicine, Hospital de Clı́nicas de Porto Alegre – HCPA, Porto Alegre, RS, Brazil

c Department of Hematology and Bone Marrow Transplant, Hospital de Clı́nicas de Porto Alegre, Porto Alegre, RS, Brazil

Corresponding Author InformationCorresponding author. Tel.: +55-51-33-16-67-40; fax: +55-51-33-16-73-11

PII: S0306-9877(04)00331-7

doi:10.1016/j.mehy.2004.05.004


View previous. 6 of 49 View next.